Health
STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
Publication: STAT
Author: Ed Silverman
Source published: 09/11/2026, 14:28:42 UTC
Briefing created: 22/11/2026, 20:58:55 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 11:22:24 UTC.
Briefings
Novartis is abandoning an experimental heart drug after a study showed it failed to prevent cardiovascular deaths, while the Biotechnology Innovation Organization (BIO) filed a lawsuit against the Trump administration's Global Benchmark for Efficient Drug Pricing (GLOBE) pilot program. The lawsuit challenges the model's authority over Medicare Part B drugs administered in doctor offices, though the administration has exempted most companies from enforcement. The article notes that Novartis previously considered this drug a potential blockbuster but found little promise for preventing heart attacks.
Key points
- Novartis is abandoning an experimental heart drug after a study showed it failed to prevent cardiovascular deaths.
- The Biotechnology Innovation Organization (BIO) filed a lawsuit against the Trump administration's Global Benchmark for Efficient Drug Pricing (GLOBE) pilot program, challenging its authority over Medicare Part B drugs administered in doctor offices.
Context
The article reports on a Novartis study presented at the American Heart Association meeting that found the experimental drug had little promise for preventing heart attacks and cardiovascular deaths. It also details a legal battle between BIO and the Trump administration regarding drug pricing models for Medicare, noting the administration has exempted most companies from enforcement despite the lawsuit.
Limitations
The evidence is limited to a single article from November 2026 reporting on a Novartis study and a BIO lawsuit. It does not provide specific dates for the study results, exact numbers of patients affected by the drug failure, or details on the GLOBE program's specific impact on Medicare Part B drugs administered in doctor offices.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 20:58:55 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
IPFS archive pending.